Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, as it prepares to launch its popular ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Zepbound, the weight-loss version of diabetes drug Mounjaro ... they said. Zepbound is expected to be approved as a treatment for heart failure later this year as well, they noted, expanding ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

While Zepbound is FDA-approved for weight loss, Mounjaro is approved for managing ... and half maintained it after three years. Adults lost an average of 8% of their body weight over 56 weeks ...

Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.